S Ramesh

PK Das will take over from current Chairman S Ramesh, who retires on December 31.

Big Deal: Deal street's outlook for 2017

Watch S Ramesh, MD & CEO at Kotak Investment Banking and Sourav Mallik, Joint MD at Kotak Investment Banking speaking with Nisha Poddar of CNBC-TV18 about deal street's outlook for 2017.

Listing of renewable cos to get a good response: S Ramesh

Speaking to CNBC-TV18, Ramesh said that a few top companies from the renewables space are likely to get listed and will receive a good response from the market.

Can grow at 18%; expect margins at 30% going ahead: Lupin

"If the gross domestic product (GDP) is around 7-8 percent for the country and pharma sector grows at 10-12 percent, Lupin can grow at 18 percent going ahead on the back of its strong strategies," says S Ramesh, CFO of the company.

FY17 to be 'watershed' year of double-digit earnings: Envision

In an interview with CNBC-TV18, Nilesh Shah along with S Ramesh of Kotak Investment Banking shared their views on factors that are supporting market momentum and what is to be expected going forward.

Market volatility may delay new IPO launches: S Ramesh

The current market volatility and headwinds in secondary market may delay the pace of IPO launches, S Ramesh, MD and CEO of Kotak Investment Banking.

IPO pipeline looks good, divestment to go on in FY16: Kotak

There is cause for optimism as we look at fiscal 2016. Experts say number of issuances are slated to hit the market in FY16

Lupin scouts for acquisitions in US

Terming the US as a high growth market for the company, the Mumbai-based firm said it aims to grow at around 25 percent in the world's largest drug market.

Indian business to do well in Q4FY14: Lupin

Trizivir and Zymaxid generics' contribution will remain high going ahead, S Ramesh, CFO, Lupin said.

Surprise mkt on divestments; supply not an issue: Expert

Prithvi Haldea, managing director, Prime Database says there are no supply related issues as the pipeline for public service undertakings (PSUs) for divestment is very strong. The problem, Haldea adds, is to do with the government‘s view on the fundamentals of the company and it‘s pricing in the market.

See FY14 growth at 15-20%; eye 100 launches in 3 yrs: Lupin

Lupin's S Ramesh expects 15-20 percent growth for FY14 on year-on-year basis. Going ahead, he believes the overall momentum would continue and the company will find growth.

Contraceptives basket can fetch $150m from US sales: Lupin

Pharma major Lupin expects sales in the US to touch at least USD 150 million per quarter going ahead, S Ramesh, CFO, said on Tuesday.

Novartis verdict a boost; India too big to ignore: Lupin

S Ramesh, CFO, Lupin says that the Novartis judgment will not impact market much and it is a positive for domestic pharmaceutical sector. In an interview to CNBC-TV18, he adds, "No company can think of ignoring the Indian market and I do not see MNCs going slow on investment in India."

Budget to focus on policy moves; investors buoyant: Kotak

S Ramesh, Joint MD, Kotak Investment Banking believes the upcoming Budget would be focusing more on directional moves at the fiscal side. According to him, these moves would ensure continuous foreign flows to the capital markets

See over 30% growth in next couple of quarters: Lupin

Lupin had a good year in the stock market. In an interview to CNBC-TV18, S Ramesh, president - finance & planning of Lupin says in the first two quarters of the current year, the company has exhibited more than 30 percent growth. "We are fairly confident that we will be able to sustain this in the next couple of quarters," he asserts.

No rivals for Suprax; Lupin eyes 22-25% domestic growth

Pharmaceutical company Lupin has become the latest entrant to the Nifty and will be indexed from September 28. The stock has been an outperformer over the months and S Ramesh, CFO of Lupin expects the company's domestic growth to be maintained at 22-25%.

'SEBI move to structurally alter nature of MF industry'

The market regulator granted asset management companies (AMCs) flexibility on fees by allowing them to charge up to 30 basis points more as total expense ratio (TER) across schemes from inflows from smaller towns beyond the top 15 cities. S Ramesh, Joint MD of Kotak Investment Banking and Puneet Chaddha CEO of HSBC AMC welcome this move.

Lupin sees 20-25% growth in US business in FY13

Pharma major Lupin expects its US business will grow 20-25% in fiscal 2012-13 (April-March), helped by a strong pipeline of generic drugs.

3 New Ways of Selling Down!

The New Year has brought 3 new mechanisms- 2 that help companies and their promoters to meet the minimum 25% public shareholding limit and the third helps the majority shareholder have more shares accepted in a buyback.

Lupin hopeful of getting Fortamet case through

Lupin had launched Fortamet, a diabetic drug, at risk in the US, causing an injunction against the drug. Chief Financial Officer S Ramesh clarified that Fortamet generic was launched only for few days.

Lupin aims to grow 25% in FY12, to roll out 100 products

Lupin, which has been a hot favourite among market experts, is growing ambitious. The drug company is eyeing to launch around 100 more products in the next two to three years.

Why are foreign issuers headed to Hong Kong?

It's the world's biggest bourse by market value and the biggest IPO market for the past 2 years. And Chinese companies aside,

Lupin sees more development on NeuClone deal in 5-6 qtrs

S Ramesh, CFO of Lupin, in an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, said that this agreement might bear fruit in five-six quarters. He also stated that Lupin wants a positive development in this particular area.

Why invest in an IPO: Experts explain

CNBC-TV18's special show Informed Investor, talks in more detail about the primary markets space and how to approach the potential IPOs. It discusses which one is worth a subscription and which one looks like a skip.

Govt should focus on sustenance of EOUs: Lupin

Drug firm Lupin is optimistic about performing well in the next fiscal says S Ramesh, chief financial officer of the company. The company aims to maintain 20% growth rate in the next year as well.